Download
s11739-020-02340-0.pdf 924,69KB
WeightNameValue
1000 Titel
  • Management of acute pulmonary embolism 2019: what is new in the updated European guidelines?
1000 Autor/in
  1. Konstantinides, Stavros |
  2. Meyer, Guy |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-05-26
1000 Erschienen in
1000 Quellenangabe
  • 15(6):957-966
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s11739-020-02340-0 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467952/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Pulmonary embolism (PE) is the third most frequent acute cardiovascular syndrome. Annual PE incidence and PE-related mortality rates rise exponentially with age, and consequently, the disease burden imposed by PE on the society continues to rise as the population ages worldwide. Recently published landmark trials provided the basis for new or changed recommendations included in the 2019 update of the European Society of Cardiology Guidelines (developed in cooperation with the European Respiratory Society). Refinements in diagnostic algorithms were proposed and validated, increasing the specificity of pre-test clinical probability and D-dimer testing, and thus helping to avoid unnecessary pulmonary angiograms. Improved diagnostic strategies were also successfully tested in pregnant women with suspected PE. Non-vitamin K antagonist oral anticoagulants (NOACs) are now the preferred agents for treating the majority of patients with PE, both in the acute phase (with or without a brief lead-in period of parenteral heparin or fondaparinux) and over the long term. Primary reperfusion is reserved for haemodynamically unstable patients. Besides, the 2019 Guidelines endorse multidisciplinary teams for coordinating the acute-phase management of high-risk and (in selected cases) intermediate-risk PE. For normotensive patients, physicians are advised to include the assessment of the right ventricle on top of clinical severity scores in further risk stratification, especially if early discharge of the patient is envisaged. Further important updates include guidance (1) on extended anticoagulation after PE, taking into account the improved safety profile of NOACs; and (2) on the overall care and follow-up of patients who have suffered PE, with the aim to prevent, detect and treat late sequelae of venous thromboembolism.
1000 Sacherschließung
lokal Europe [MeSH]
lokal Pulmonary embolism
lokal Factor Xa Inhibitors/therapeutic use [MeSH]
lokal Guidelines as Topic [MeSH]
lokal Humans [MeSH]
lokal Pulmonary Embolism/therapy [MeSH]
lokal Diagnosis
lokal Anticoagulation
lokal Guidelines
lokal Treatment
lokal Disease Management [MeSH]
lokal Im - Review
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/S29uc3RhbnRpbmlkZXMsIFN0YXZyb3M=|https://frl.publisso.de/adhoc/uri/TWV5ZXIsIEd1eQ==
1000 Hinweis
  • DeepGreen-ID: 094493e292c94d77833647d2b6ee24fc ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6471600.rdf
1000 Erstellt am 2023-11-18T14:26:00.635+0100
1000 Erstellt von 322
1000 beschreibt frl:6471600
1000 Zuletzt bearbeitet Thu Apr 04 09:24:00 CEST 2024
1000 Objekt bearb. Thu Apr 04 09:24:00 CEST 2024
1000 Vgl. frl:6471600
1000 Oai Id
  1. oai:frl.publisso.de:frl:6471600 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source